-7.993647855672189, BRIEF-CryoLife Announces Pricing Of $100 Million Convertible Senior Notes Offering June 19 (Reuters) - CryoLife Inc: * CRYOLIFE ANNOUNCES PRICING OF $100 MILLION CONVERTIBLE SENIOR NOTES OFFERING * CRYOLIFE - PRICING OF $100 MILLION OF 4.250% CONVERTIBLE SENIOR NOTES DUE 2025 Source text for Eikon: Further company coverage:
0.0," BRIEF-CryoLife Announces Offering Of Convertible Senior Notes Due 2025 June 18 (Reuters) - CryoLife Inc: * CRYOLIFE ANNOUNCES OFFERING OF CONVERTIBLE SENIOR NOTES DUE 2025 * CRYOLIFE INC - INTENDS TO OFFER $100 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2025 * CRYOLIFE INC - NOTES ARE EXPECTED TO PAY INTEREST SEMIANNUALLY AND WILL MATURE ON JULY 1, 2025 * CRYOLIFE INC - EXPECTS TO USE NET PROCEEDS FROM OFFERING INCLUDING REPAYMENT OF APPROXIMATELY $30 MILLION OUTSTANDING UNDER ITS REVOLVING CREDIT FACILITY Source text for Eikon: Further company coverage:"
-6.690301284891445, BRIEF-Cryolife Initiates Enrollment In Proact Xa Clinical Trial May 7 (Reuters) - CryoLife Inc: * CRYOLIFE INITIATES ENROLLMENT IN PROACT XA CLINICAL TRIAL Source text for Eikon: Further company coverage:
16.462674418604646," BRIEF-Cryolife Expects Q1 2020 Revenue To Be About $65.5 Mln April 1 (Reuters) - CryoLife Inc: * AS OF MARCH 31, 2020 CRYOLIFE HAS OVER $60 MILLION IN CASH AND CASH EQUIVALENTS * EXPECTS Q1 2020 REVENUES TO BE APPROXIMATELY $65.5 MILLION COMPARED TO Q1 2020 REVENUE GUIDANCE OF $67 MILLION TO $69 MILLION * IS WITHDRAWING ITS PREVIOUSLY ANNOUNCED Q1 AND FULL YEAR 2020 FINANCIAL GUIDANCE WHICH WAS ISSUED ON FEBRUARY 13, 2020 * CRYOLIFE - DELAYING CERTAIN RESEARCH AND DEVELOPMENT,CLINICAL RESEARCH PROJECTS THAT ARE NOT EXPECTED TO GENERATE REVENUE BEFORE 2023 BUT CONTINUING TO PURSUE THOSE THAT WILL * WHILE FULL SHORT TERM IMPACT ON US OF PANDEMIC IS NOT KNOWN * IS OPERATING ALL THREE OF ITS MANUFACTURING SITES AT NEAR FULL PRODUCTION * CRYOLIFE - ON MARCH 26,BORROWED ENTIRE AVAILABLE AMOUNT UNDER ITS $30 MILLION REVOLVING CREDIT FACILITY AS A PRECAUTIONARY MEASURE TO INCREASE CASH * HAS TAKEN PRE-EMPTIVE STEPS TO CURTAIL SPENDING Source text for Eikon: Further company coverage:"
-7.465626425712127, BRIEF-Cryolife Receives CE Mark For E-Vita Open Neo Hybrid Stent Graft March 4 (Reuters) - CryoLife Inc: * CRYOLIFE RECEIVES CE MARK FOR E-VITA OPEN NEO™ HYBRID STENT GRAFT Source text for Eikon: Further company coverage:
-8.928571074263052, BRIEF-Cryolife Receives CE Mark For On-X Ascending Aortic Prosthesis Feb 27 (Reuters) - CryoLife Inc: * CRYOLIFE RECEIVES CE MARK FOR ON-X® ASCENDING AORTIC PROSTHESIS Source text for Eikon: Further company coverage:
-30.99009673234643," BRIEF-Cryolife Q4 Revenue $69.7 Mln Vs Refinitiv Ibes Estimate Of $70.8 Mln Feb 13 (Reuters) - CryoLife Inc: * CRYOLIFE REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS * Q4 REVENUE $69.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $70.8 MILLION * Q4 EARNINGS PER SHARE ESTIMATE $0.08 -- REFINITIV IBES DATA * “2020 REVENUE GUIDANCE ASSUMES NO CONTRIBUTION DURING 2020 FROM BIOGLUE IN CHINA, PERCLOT IN U.S., OR TMR HANDPIECES” * Q4 REVENUE VIEW $70.8 MILLION -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:"
